ABSTRACT
Background & objectives: β-thalassaemia is a genetic disorder and an important health problem around the world. Quantitative haemoglobin A2 (HbA2) levels are used for the diagnosis of β-thalassaemia. The conventional methods are high performance liquid chromatography (HPLC), electrophoresis, and microcolumn chromatography techniques. We established a fast protein liquid chromatography (FPLC) method, to measure quantitatively of HbA2 levels, and compared its efficacy with conventional methods. Methods: The FPLC method, using a DEAE Sepharose, Hi Trap anion-exchange column chromatography technique was set up for HbA2 measurement. In this study, 220 blood samples were screened for haemoglobin type by FPLC technique and also using HPLC, microcolumn chromatography and electrophoresis. Results: The FPLC results were highly correlated (r = 0.985, P<0.001) with those of HPLC for quantification of HbA2 as well as cellulose acetate electrophoresis (r = 0.977) and microcolumn chromatography (r = 0.980). The FPLC method showed 100 per cent sensitivity and specificity, positive and negative predictive value for β-thalassaemia diagnosis. In addition, the FPLC method was simple, rapid, low cost and reproducible. The HbA2/E range of FPLC for β-thalassaemia was 6-10 per cent, HbE trait was 10-40 per cent, β-thalassaemia/HbE was 40-60 per cent and homozygous HbE was more than 60 per cent. Interpretation & conclusions: Our findings suggested that FPLC method could be used as a cost-effective method for routine β-thalassaemia diagnosis.
Subject(s)
Adult , Chromatography, Ion Exchange/economics , Chromatography, Ion Exchange/methods , Chromatography, Ion Exchange/standards , Chromatography, Liquid/economics , Chromatography, Liquid/methods , Chromatography, Liquid/standards , Cost-Benefit Analysis , Electrophoresis/economics , Electrophoresis/methods , Electrophoresis/standards , Fetal Hemoglobin/analysis , Fetal Hemoglobin/isolation & purification , Hemoglobin A2/analysis , Hemoglobin A2/isolation & purification , Hemoglobin E/analysis , Hemoglobin E/isolation & purification , Hemoglobins/analysis , Hemoglobins/isolation & purification , Humans , Mass Screening/economics , Mass Screening/methods , Mass Screening/standards , Predictive Value of Tests , Sensitivity and Specificity , beta-Thalassemia/diagnosisABSTRACT
Hemopressin (PVNFKFLSH), a novel bioactive peptide derived from the alpha1-chain of hemoglobin, was originally isolated from rat brain homogenates. Hemopressin causes hypotension in anesthetized rats and is metabolized in vivo and in vitro by endopeptidase 24.15 (EP24.15), neurolysin (EP24.16), and angiotensin-converting enzyme (ACE). Hemopressin also exerts an antinociceptive action in experimental inflammatory hyperalgesia induced by carrageenin or bradykinin via a mechanism that is independent of opioids. These findings suggest that this peptide may have important regulatory physiological actions in vivo.